SEC 13F Intelligence

Managers / Q2 2024 · view latest →

SUVRETTA CAPITAL MANAGEMENT, LLC

CIK 0001569064 · 540 MADISON AVENUE, 7TH FLOOR, NEW YORK, NY, 10022 · 2127025204

Reported Value
$2.7B
Q2 2024
Positions
98
Filings on Record
32
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Suvretta Capital Management, LLC reported $2.7B in U.S.-listed holdings across 98 positions for Q2 2024.

Its largest position, Biohaven, represents 6.6% of the portfolio.

Compared with Q1 2024, the fund opened 9 new positions and exited 12.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $1.7BQ4 ’18Q1 ’19: $3.5BQ2 ’19: $4.7BQ3 ’19: $3.9BQ4 ’19: $4.4BQ4 ’19Q1 ’20: $3.7BQ2 ’20: $4.7BQ3 ’20: $5.6BQ4 ’20: $7.0BQ4 ’20Q1 ’21: $6.8BQ2 ’21: $6.7BQ3 ’21: $5.9BQ4 ’21: $5.2BQ4 ’21Q1 ’22: $3.3BQ2 ’22: $2.6BQ3 ’22: $2.4BQ4 ’22: $2.4BQ4 ’22Q1 ’23: $2.4BQ2 ’23: $1.9BQ3 ’23: $1.9BQ4 ’23: $2.2BQ4 ’23Q1 ’24: $2.7BQ2 ’24: $2.7BQ3 ’24: $3.1BQ4 ’24: $2.9BQ4 ’24Q1 ’25: $2.7BQ2 ’25: $3.3BQ3 ’25: $3.9BQ4 ’25: $4.9BQ4 ’25Q1 ’26: $3.9Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 73.1%Other: 13.9%ETP: 10.0%ADR: 2.9%
  • Common Stock · 73.1% · $2.0B
  • Other · 13.9% · $380M
  • ETP · 10.0% · $272M
  • ADR · 2.9% · $80M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SYYSYSCO CORPNEW+520.9K520.9K+$37M$37M
CTNMCONTINEUM THERAPEUTICS INCNEW+2.05M2.05M+$36M$36M
ERASERASCA INCNEW+13.77M13.77M+$32M$32M
MCDMCDONALDS CORPNEW+110.4K110.4K+$28M$28M
TSLATESLA INCNEW+134.9K134.9K+$27M$27M
ABEOABEONA THERAPEUTICS INCNEW+3.69M3.69M+$16M$16M
GLUEMONTE ROSA THERAPEUTICS INCNEW+2.66M2.66M+$10M$10M
EXKEXACT SCIENCES CORPNEW+94.1K94.1K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BIOHAVEN LTDCOM6.63%$180M5.20M
2IM8NINSMED INCCOM PAR $.016.21%$169M2.52M
3KURAKURA ONCOLOGY INCCOM5.35%$146M7.07M
4ITCIEURINTRA-CELLULAR THERAPIES INCCOM3.94%$107M1.57M
5ARQTARCUTIS BIOTHERAPEUTICS INCCOM3.42%$93M10.00M
6RAREULTRAGENYX PHARMACEUTICAL INCOM3.11%$85M2.06M
7METAMETA PLATFORMS INCCL A3.10%$84M167.2K
8ACLXGBXARCELLX INCCOMMON STOCK3.07%$84M1.52M
9UNHUNITEDHEALTH GROUP INCCOM3.02%$82M161.5K
10AAPLAPPLE INCCOM2.81%$77M363.4K
11AMZNAMAZON COM INCCOM2.53%$69M356.3K
12ETNBGBP89BIO INCCOM2.36%$64M8.03M
13TSMTAIWAN SEMICONDUCTOR MFG LTDSPONSORED ADS2.24%$61M350.8K
14AMDADVANCED MICRO DEVICES INCCOM2.06%$56M346.0K
15ELVELEVANCE HEALTH INCCOM1.82%$50M91.4K
164XC1KALVISTA PHARMACEUTICALS INCCOM1.81%$49M4.19M
17ROYALTY PHARMA PLCSHS CLASS A1.81%$49M1.87M
18MSFTMICROSOFT CORPCOM1.71%$46M104.0K
19EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW1.65%$45M5.18M
20APOAPOLLO GLOBAL MGMT INCCOM1.54%$42M354.5K
21TAT&T INCCOM1.54%$42M2.19M
22SYYSYSCO CORPCOM1.37%$37M520.9K
23CTNMCONTINEUM THERAPEUTICS INCCL A1.33%$36M2.05M
24KOCOCA COLA COCOM1.31%$36M560.6K
25GSGOLDMAN SACHS GROUP INCCOM1.30%$35M77.9K
26ORCLORACLE CORPCOM1.27%$35M245.1K
27GE AEROSPACECOM NEW1.20%$33M205.0K
28ERASERASCA INCCOM1.19%$32M13.77M
29CRH PLCORD1.19%$32M432.0K
30AVBPARRIVENT BIOPHARMA INCCOM1.17%$32M1.71M
31MCDMCDONALDS CORPCOM1.03%$28M110.4K
32FERGUSON PLC NEWSHS1.03%$28M145.0K
33TSLATESLA INCCOM0.98%$27M134.9K
34BACVERIZON COMMUNICATIONS INCCOM0.92%$25M609.9K
35CMGCHIPOTLE MEXICAN GRILL INCCOM0.92%$25M398.5K
36PEPGPEPGEN INCCOM0.89%$24M1.52M
37PROKIDNEY CORPCLASS A ORD SHS0.84%$23M9.34M
38SUTRO BIOPHARMA INCCOM0.83%$23M7.71M
39BSXBOSTON SCIENTIFIC CORPCOM0.71%$19M251.7K
40PINSPINTEREST INCCL A0.66%$18M410.0K
41ZURA BIO LTDCLASS A ORD SHS0.62%$17M4.86M
42FULCFULCRUM THERAPEUTICS INCCOM0.58%$16M2.54M
43ABEOABEONA THERAPEUTICS INCCOM NEW0.57%$16M3.69M
44RCUSARCUS BIOSCIENCES INCCOM0.54%$15M957.3K
45JNJJOHNSON & JOHNSONCOM0.48%$13M90.1K
46BNTCBENITEC BIOPHARMA INCCOM NEW0.43%$12M1.69M
47IMMATICS N.VSHS0.40%$11M946.6K
48SNYSANOFISPONSORED ADR0.38%$10M210.7K
49INFLARX NVCOM0.37%$10M5.73M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$3.9B89May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$4.9B93Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$3.9B93Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$3.3B98Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$2.7B100May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$2.9B96Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3.1B98Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$2.7B98Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.7B101May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.2B88Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$1.9B87Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.9B100Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$2.4B95May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$2.4B89Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$2.4B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.6B89Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$3.3B87May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$5.2B95Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$5.9B106Nov 16, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$6.7B122Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$6.8B106May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$7.0B106Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$5.6B94Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$4.7B80Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$3.7B65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$4.4B39Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$3.9B42Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$4.7B47Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$3.5B38May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$1.7B22Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.